Emerald Star Holdings, LLC is a leading scientific company based in Seattle, WA, specializing in early development assays, preclinical protein sciences, and bioanalytical services. With a strong focus on translational sciences and assay development, they offer expertise in infectious diseases, vaccines, immunotherapy, immuno-oncology, and metabolic diseases. Their team of renowned scientists and state-of-the-art laboratories enable them to provide comprehensive support to pharmaceutical and biotech companies in advancing their molecules to market.
Nexelis, a Q Solutions company and a subsidiary of Emerald Star Holdings, LLC, is dedicated to immunology and vaccines. With over 20 years of experience in vaccine testing, Nexelis offers cutting-edge technology platforms, in-house custom in vivo services, and protein sciences capabilities to support candidate selection and assay development. They also specialize in immuno-oncology, providing functional profiling and evaluation of immunogenicity for candidate therapeutics. Additionally, Nexelis offers expertise in immunogenicity assessment and monitoring for biologics, as well as a long-standing history in the metabolic field. Through acquisitions and partnerships, they continue to expand their capabilities and excel in the scientific collaboration for various diseases and conditions.
Generated from the website